Latest Financial Results News

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Pengana Private Equity Trust reported a significant decline in half-year profit for the period ending 31 December 2025, yet increased its interim distribution to unitholders. The Trust’s net asset value per unit showed a modest rise despite challenging market conditions.

Globe International reported a 3.1% revenue increase to $98.2 million for the half-year ended December 2025, despite a 27% drop in EBIT due to unexpected US tariffs. The company maintains its interim dividend, signalling steady shareholder returns amid geopolitical challenges.

StepChange Holdings Limited reports a strong half-year performance post-IPO, with $24.36 million in revenue and a net profit of $524,400, underpinned by key acquisitions and US expansion.

Desane Group Holdings reports a modest half-year profit with stable assets and gearing, completes a key property sale, and pushes forward with a major industrial development in Penrith.

Bapcor Limited reported a statutory loss of $104.8 million for the first half of FY26 and announced a fully underwritten $200 million equity raising to strengthen its balance sheet and support operational recovery.

TZ Limited reported a $1.92 million loss for the half-year ending December 2025, with revenues of $5.4 million impacted by delayed US projects and integration challenges from its Keyvision acquisition. The company is banking on large tenders and expanding Microsoft data centre sales to drive recovery.

NTAW Holdings reported a reduced half-year loss of $9.7 million on a 12.3% revenue decline, driven by operational challenges and brand distribution changes. The company is focusing on cost restructuring and strategic partnerships to restore growth.

Metrics Real Estate Multi-Strategy Fund has reported a striking increase in half-year profit and distributions, underpinned by strong commercial real estate investments across debt and equity portfolios.

Neuren Pharmaceuticals reports a 15% rise in 2025 royalties from its partner Acadia’s DAYBUE sales, with strong 2026 guidance signalling further growth. The launch of a new powder formulation and ongoing regulatory efforts in Europe and Japan add to the momentum.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Cettire Limited reported a 2.8% revenue decline to $382.8 million and a net loss of $1.05 million for the half-year ended 31 December 2025, impacted by softer US demand and rising costs. Despite these headwinds, the company maintains a strong cash position and is focused on profitable growth.